Vistagen Therapeutics Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance

summarizeSummary

Vistagen Therapeutics received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Minimum Bid Price Non-Compliance

  Vistagen Therapeutics, Inc. received a notice from Nasdaq on February 3, 2026, indicating non-compliance with the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)) due to its common stock trading below $1.00 for 30 consecutive business days.

• 180-Day Compliance Period Initiated

  The company has 180 calendar days, until August 3, 2026, to regain compliance. To do so, its common stock must close at $1.00 per share or more for at least 10 consecutive business days.

• Potential for Delisting

  While the notice has no immediate effect on the stock's listing, failure to regain compliance within the initial period, or any subsequent extension, could result in the delisting of the company's common stock from the Nasdaq Capital Market.

auto_awesomeAnalysis

Vistagen Therapeutics has received a critical notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement. This is a significant event for the company, as continued non-compliance could lead to delisting from the Nasdaq Capital Market, which would severely impact its liquidity, investor confidence, and ability to raise capital. The company now has 180 days to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. While there's a possibility of a second 180-day period, the current stock price of $0.5632 indicates a substantial challenge ahead. Investors should monitor the company's efforts to address this issue, as failure to regain compliance poses a material risk to the stock's exchange listing.